{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:07:15Z","timestamp":1792602435147,"version":"4.5.0"},"reference-count":59,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.14874","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T06:53:26Z","timestamp":1736232806000},"source":"Crossref","is-referenced-by-count":7,"title":["DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines"],"prefix":"10.3892","volume":"29","author":[{"given":"Tassanee","family":"Lerksuthirat","sequence":"first","affiliation":[{"name":"Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunisa","family":"Prasopporn","sequence":"additional","affiliation":[{"name":"Siriraj Center of Research for Excellence (SiCORE) for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakkreat","family":"Wikiniyadhanee","sequence":"additional","affiliation":[{"name":"Program in Translational Medicine, Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samutprakarn 10540, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermsiri","family":"Chitphuk","sequence":"additional","affiliation":[{"name":"Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasana","family":"Stitchantrakul","sequence":"additional","affiliation":[{"name":"Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paravee","family":"Owneium","sequence":"additional","affiliation":[{"name":"Program in Translational Medicine, Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samutprakarn 10540, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwanon","family":"Jirawatnotai","sequence":"additional","affiliation":[{"name":"Siriraj Center of Research for Excellence (SiCORE) for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donniphat","family":"Dejsuphong","sequence":"additional","affiliation":[{"name":"Program in Translational Medicine, Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samutprakarn 10540, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"key20250207091914_b1-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"key20250207091914_b2-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20250207091914_b3-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/cncr.34541","article-title":"The multidisciplinary management of cholangiocarcinoma","volume":"129","author":"Ohaegbulam","year":"2023","journal-title":"Cancer"},{"key":"key20250207091914_b4-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.critrevonc.2016.11.012","article-title":"Cholangiocarcinoma","volume":"116","author":"Squadroni","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20250207091914_b5-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3390\/cells11091463","article-title":"DNA damage response inhibitors in cholangiocarcinoma: Current progress and perspectives","volume":"11","author":"G\u00f6n\u00fcl Geyik","year":"2022","journal-title":"Cells"},{"key":"key20250207091914_b6-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2019.07.022","article-title":"Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker","volume":"120","author":"Chae","year":"2019","journal-title":"Eur J Cancer"},{"key":"key20250207091914_b7-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/cco.2020.02.02","article-title":"Biliary tract cancer and genomic alterations in homologous recombinant deficiency: Exploiting synthetic lethality with PARP inhibitors","volume":"9","author":"Ahn","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"key20250207091914_b8-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-cancerbio-042016-073434","article-title":"Synthetic lethality in cancer therapeutics","volume":"1","author":"Beijersbergen","year":"2017","journal-title":"Annu Rev Cancer Biol"},{"key":"key20250207091914_b9-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"key20250207091914_b10-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair (Amst)"},{"key":"key20250207091914_b11-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"key20250207091914_b12-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1158\/1078-0432.CCR-17-1337","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20250207091914_b13-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"key20250207091914_b14-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s40265-018-1004-5","article-title":"Talazoparib: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"key20250207091914_b15-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-20-3546","article-title":"An open-label, multicenter, single-arm, phase II study of fluzoparib in patients with germline BRCA1\/2 mutation and platinum-sensitive recurrent ovarian cancer","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20250207091914_b16-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/cam4.3575","article-title":"Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer","volume":"10","author":"Xu","year":"2021","journal-title":"Cancer Med"},{"key":"key20250207091914_b17-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"key20250207091914_b18-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/PPO.0000000000000561","article-title":"DNA damage repair inhibitors-combination therapies","volume":"27","author":"Smith","year":"2021","journal-title":"Cancer J"},{"key":"key20250207091914_b19-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/d41573-022-00092-4","article-title":"DNA damage response drugs for cancer yield continued synthetic lethality learnings","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"key20250207091914_b20-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol Oncol"},{"key":"key20250207091914_b21-ol-29-3-14874","article-title":"NCT03330847: To assess safety and efficacy of agents targeting DNA damage repair with olaparib versus olaparib monotherapy","author":"Clinical"},{"key":"key20250207091914_b22-ol-29-3-14874","article-title":"NCT03787680: Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP Trial)","author":"Clinical"},{"key":"key20250207091914_b23-ol-29-3-14874","article-title":"NCT03878095: Testing olaparib and AZD6738 in IDH1 and IDH2 mutant tumors","author":"Clinical"},{"key":"key20250207091914_b24-ol-29-3-14874","article-title":"NCT04298021: DDR-umbrella study of DDR targeting agents in advanced biliary tract cancer","author":"Clinical"},{"key":"key20250207091914_b25-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1158\/1078-0432.CCR-22-2551","article-title":"Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation","volume":"29","author":"Serra-Camprub\u00ed","year":"2023","journal-title":"Clin Cancer Res"},{"key":"key20250207091914_b26-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.3390\/cancers13174405","article-title":"Niraparib suppresses cholangiocarcinoma tumor growth by inducing oxidative and replication stress","volume":"13","author":"Bezrookove","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20250207091914_b27-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/jpp\/rgaa050","article-title":"The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells","volume":"73","author":"Moolmuang","year":"2021","journal-title":"J Pharm Pharmacol"},{"key":"key20250207091914_b28-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2021.05.029","article-title":"ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer","volume":"516","author":"Nam","year":"2021","journal-title":"Cancer Lett"},{"key":"key20250207091914_b29-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/01.TP.0000110292.73873.25","article-title":"Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT","volume":"77","author":"Maruyama","year":"2004","journal-title":"Transplantation"},{"key":"key20250207091914_b30-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF01851205","article-title":"Establishment and characterization of a cell line from a human cholangiocellular carcinoma","volume":"188","author":"Kusaka","year":"1988","journal-title":"Res Exp Med (Berl)"},{"key":"key20250207091914_b31-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1620\/tjem.177.61","article-title":"Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1","volume":"177","author":"Saijyo","year":"1995","journal-title":"Tohoku J Exp Med"},{"key":"key20250207091914_b32-ol-29-3-14874","first-page":"O11","article-title":"Establishment of cholangiocarcinoma organoids from long-term frozen tissues","volume":"2","author":"Suntiparpluacha","year":"2022","journal-title":"J Basic Appl Pharmacol"},{"key":"key20250207091914_b33-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"105182","DOI":"10.1016\/j.isci.2022.105182","article-title":"Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma","volume":"25","author":"Jamnongsong","year":"2022","journal-title":"iScience"},{"key":"key20250207091914_b34-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of american pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"key20250207091914_b35-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"key20250207091914_b36-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"key20250207091914_b37-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"key20250207091914_b38-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s13273-021-00121-0","article-title":"RepID-deficient cancer cells are sensitized to a drug targeting p97\/VCP segregase","volume":"17","author":"Jang","year":"2021","journal-title":"Mol Cell Toxicol"},{"key":"key20250207091914_b39-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/2211-5463.12954","article-title":"TRIM29 is required for efficient recruitment of 53BP1 in response to DNA double-strand breaks in vertebrate cells","volume":"10","author":"Wikiniyadhanee","year":"2020","journal-title":"FEBS Open Bio"},{"key":"key20250207091914_b40-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/biom10121680","article-title":"DNA Repair Biosensor-Identified DNA Damage Activities of Endophyte Extracts from Garcinia cowa","volume":"10","author":"Lerksuthirat","year":"2020","journal-title":"Biomolecules"},{"key":"key20250207091914_b41-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"key20250207091914_b42-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/cancers14040953","article-title":"Everything comes with a price: The toxicity profile of DNA-damage response targeting agents","volume":"14","author":"Martorana","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20250207091914_b43-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"107450","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as cancer therapy: A new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol Ther"},{"key":"key20250207091914_b44-ol-29-3-14874","article-title":"NCT03462342: Combination ATR and PARP inhibitor (CAPRI) trial with AZD6738 and olaparib in recurrent ovarian cancer (CAPRI)","author":"Clinical"},{"key":"key20250207091914_b45-ol-29-3-14874","article-title":"NCT05269316: Study to evaluate IMP9064 as a monotherapy or in combination in patients with advanced solid tumors","author":"Clinical"},{"key":"key20250207091914_b46-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"key20250207091914_b47-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.4143\/crt.2018.526","article-title":"Therapeutic targeting of the DNA damage response using an ATR inhibitor in biliary tract cancer","volume":"51","author":"Nam","year":"2019","journal-title":"Cancer Res Treat"},{"key":"key20250207091914_b48-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1038\/s41467-022-32023-7","article-title":"Therapeutic targeting of ATR in alveolar rhabdomyosarcoma","volume":"13","author":"Dorado Garcia","year":"2022","journal-title":"Nat Commun"},{"key":"key20250207091914_b49-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.3390\/cancers13246215","article-title":"Increased replication stress determines ATR inhibitor sensitivity in neuroblastoma cells","volume":"13","author":"King","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20250207091914_b50-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: Enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br J Cancer"},{"key":"key20250207091914_b51-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1111\/cas.15845","article-title":"Emerging strategies for cancer therapy by ATR inhibitors","volume":"114","author":"Yano","year":"2023","journal-title":"Cancer Sci"},{"key":"key20250207091914_b52-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12575-020-00133-5","article-title":"Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: Review of radiosensitivity assays","volume":"22","author":"Sadeghi","year":"2020","journal-title":"Biol Proced Online"},{"key":"key20250207091914_b53-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"zcab018","DOI":"10.1093\/narcan\/zcab018","article-title":"Targeting IDH1\/2 mutant cancers with combinations of ATR and PARP inhibitors","volume":"3","author":"Sule","year":"2021","journal-title":"NAR Cancer"},{"key":"key20250207091914_b54-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"key":"key20250207091914_b55-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.3390\/cancers12082054","article-title":"PARP inhibitor resistance mechanisms and implications for post-progression combination therapies","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20250207091914_b56-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1111\/cas.15477","article-title":"Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes","volume":"113","author":"Onji","year":"2022","journal-title":"Cancer Sci"},{"key":"key20250207091914_b57-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20250207091914_b58-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"11600","DOI":"10.1093\/nar\/gkac948","article-title":"PARP1 proximity proteomics reveals interaction partners at stressed replication forks","volume":"50","author":"Mosler","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"key20250207091914_b59-ol-29-3-14874","doi-asserted-by":"publisher","first-page":"e202302067","DOI":"10.26508\/lsa.202302067","article-title":"RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trapping","volume":"6","author":"Zamalloa","year":"2023","journal-title":"Life Sci Alliance"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T07:19:24Z","timestamp":1738912764000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.14874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,7]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.14874","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"128"}}